Several of these small-molecule inhibitors, such as gefitinib, erlotinib, and afatinib, have been authorized as initial treatment options for lung cancer patients harbouring confirmed EGFR mutations.25,26 Cetuximab and panitumumab are also the most frequently used monoclonal antibodies that target and neutralize EGFR, commonly utilized in the treatment of head and neck cancers as well as metastatic colorectal cancer.27–29 Mechanistically, these agents function by blocking ligand binding, thereby suppressing receptor activation and subsequent downstream signaling. This evidence concerns the gene EGFR and head and neck cancer.